RECRUITING

Cardiac Power Output in Cardiogenic Shock Patients

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

Official Title

Myocardial Reserve in Advanced Heart Failure Patients

Quick Facts

Study Start:2023-07-06

Study Completion:2025-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05700617

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. LVEF ≤ 35% 2. Referred for RHC for: 1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR 2. Accurate assessment of invasive hemodynamics due to worsening clinical status, OR 3. Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR 4. Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI 3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2 4. Age ≥ 18 years-old 5. Intent for admission based on RHC data	1. eGFR \< 30 ml/min/1.73 m2 2. Severe, non-revascularized coronary artery disease 3. Concurrent acute coronary syndrome 4. Age \< 18 years-old 5. History of significant ventricular arrhythmia without an ICD

Inclusion Criteria

Exclusion Criteria

1. LVEF ≤ 35%
2. Referred for RHC for:
1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
2. Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
3. Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
4. Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
4. Age ≥ 18 years-old
5. Intent for admission based on RHC data

1. eGFR \< 30 ml/min/1.73 m2
2. Severe, non-revascularized coronary artery disease
3. Concurrent acute coronary syndrome
4. Age \< 18 years-old
5. History of significant ventricular arrhythmia without an ICD

Contacts and Locations

Study Contact

David Onsager, MD

CONTACT

7737021000

donsager1@uchgicagomedicine.org

Daniel Rodgers

CONTACT

drodgers3@uchgicagomedicine.org

Principal Investigator

Valluvan Jeevanandam, MD

PRINCIPAL_INVESTIGATOR

University of Chicago

Study Locations (Sites)

The University of Chicago

Chicago, Illinois, 60637

United States

Collaborators and Investigators

Sponsor: University of Chicago

Valluvan Jeevanandam, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-06

Study Completion Date2025-05

Study Record Updates

Study Start Date2023-07-06

Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

Heart Failure
Cardiogenic Shock